Mucoadhesive Chitosan–Dextran Sulfate Nanoparticles for Sustained Drug Delivery to the Ocular Surface

Chaiyasan, Wanachat; Srinivas, Sangly P.; Tiyaboonchai, Waree

doi:10.1089/jop.2012.0193

Cited by 71 publications

(41 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The retention of IND-NLCs on the corneal surface was determined using an experimental setup previously described by Chaiyasan et al [17]. Porcine eyes were obtained from the local slaughterhouse.…”

Section: Ex Vivo Mucoadhesive Studymentioning

confidence: 99%

Development and Characterization of Indomethacin-Loaded Mucoadhesive Nanostructured Lipid Carriers for Topical Ocular Delivery

2018

Self Cite

View full text Add to dashboard Cite

Objective: To develop and characterize indomethacin loaded-nanostructured lipid carriers (IND-NLCs) for topical ophthalmic delivery with different particle sizes and polymer coating to improve the mucoadhesive property on the ocular surface.Methods: Nanostructured lipid carriers (NLCs) with different solid lipids and surfactants were prepared by the high-pressure homogenization technique. The optimized IND-NLCs was coated with polyethylene glycol 400 (PEG). The physicochemical properties and entrapment efficacy (EE) were examined. In vitro release studies were investigated using the shake-flask method. Ex vivo mucoadhesive studies were assessed by the wash-off test. In addition, the cytotoxicity was assessed by the short time exposure test.Results: IND-NLCs of ~300 and ~40 nm in diameter were successfully produced with a zeta potential of -30 mV and EE of 60–70 %. IND-NLCs prepared with Tween 80 as surfactant could be sterilized by autoclaving. The PEG coating of IND-NLCs did not affect either the particle size or EE. In vitro release showed a prolonged release for 360 min with a burst release of 50-60% occurring within 5 min. The smaller-sized IND-NLCs showed slightly faster release rates and better mucoadhesion to cornea compared to the larger IND-NLCs. PEG-coated IND-NLCs showed the highest mucoadhesion. In addition, IND-NLCs showed less cytotoxicity compared to IND alone. Conclusion: The small and PEG-coated NLCs represents a potentially useful carrier for safe delivery of indomethacin to the ocular surface with increased residence time.

show abstract

Section: Ex Vivo Mucoadhesive Studymentioning

confidence: 99%

Development and Characterization of Indomethacin-Loaded Mucoadhesive Nanostructured Lipid Carriers for Topical Ocular Delivery

2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…The nanoparticles were stable to lysozymes and showed prolonged adherence to the corneal surface. 157 Several other groups have also developed dendrimer based nanocarrier systems for the treatment of ocular disease. 158 …”

Section: Nanomedicine As An Emerging Therapeutic Approach For Real mentioning

confidence: 99%

Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation

et al. 2013

View full text Add to dashboard Cite

The advent of nanotechnology has reignited interest in the field of pharmaceutical science for the development of nanomedicine. Nanomedicinal formulations are nanometer-sized carrier materials designed for increasing the drug tissue bioavailability, thereby improving the treatment of systemically applied chemotherapeutic drugs. Nanomedicine is a new approach to deliver the pharmaceuticals through different routes of administration with safer and more effective therapies compared to conventional methods. To date, various kinds of nanomaterials have been developed over the years to make delivery systems more effective for the treatment of various diseases. Even though nanomaterials have significant advantages due to their unique nanoscale properties, there are still significant challenges in the improvement and development of nanoformulations with composites and other materials. Here in this review, we highlight the nanomedicinal formulations aiming to improve the balance between the efficacy and the toxicity of therapeutic interventions through different routes of administration and how to design nanomedicine for safer and more effective ways to improve the treatment quality. We also emphasize the environmental and health prospects of nanomaterials for human health care.

show abstract

“…The subsequent in vitro and in vivo studies demonstrated that these hybrid nanoparticles could slowly release pilocarpine for 24 h to decrease the pupil diameter of rabbits (miosis effect) more effectively than pilocarpine in liposome, gel and eye drop formulations. Hybrid nanoparticles made of chitosan and dextran sulfate with around 400 nm particle size and around 40 mV zeta potential were stable in the presence of lysozyme for at least 4 h and showed at least 60 min prolonged adherence to the ex vivo porcine corneal surface [117]. After topical instillation of mucoadhesive chitosan-dextran sulfate nanoparticles (~400 nm size/+48 mV zeta potential; FITC labelled), the nanoparticles showed prolonged retention on porcine ocular surface for more than 4 h, and could be endocytosed into the ex vivo porcine corneal epithelial cells via clathrin-dependent pathway (Figure 9) [125].…”

Section: Nanoparticles For Drug Delivery To the Anterior Segmentmentioning

confidence: 99%

Nanoparticles for drug delivery to the anterior segment of the eye

Janagam

Lowe

2017

Advanced Drug Delivery Reviews

280

165

View full text Add to dashboard Cite

Commercially available ocular drug delivery systems are effective but less efficacious to manage diseases/disorders of the anterior segment of the eye. Recent advances in nanotechnology and molecular biology offer a great opportunity for efficacious ocular drug delivery for the treatments of anterior segment diseases/disorders. Nanoparticles have been designed for preparing eye drops or injectable solutions to surmount ocular obstacles faced after administration. Better drug pharmacokinetics, pharmacodynamics, non-specific toxicity, immunogenicity, and biorecognition can be achieved to improve drug efficacy when drugs are loaded in the nanoparticles. Despite the fact that a number of review articles have been published at various points in the past regarding nanoparticles for drug delivery, there is not a review yet focusing on the development of nanoparticles for ocular drug delivery to the anterior segment of the eye. This review fills in the gap and summarizes the development of nanoparticles as drug carriers for improving the penetration and bioavailability of drugs to the anterior segment of the eye.

show abstract

Mucoadhesive Chitosan–Dextran Sulfate Nanoparticles for Sustained Drug Delivery to the Ocular Surface

Abstract: Cationic and biocompatible mucoadhesive CDNs have been developed for sustained drug delivery to the ocular surface. The CDNs were stable to lysozyme and showed prolonged adherence to the corneal surface.

Cited by 71 publications

References 35 publications

Development and Characterization of Indomethacin-Loaded Mucoadhesive Nanostructured Lipid Carriers for Topical Ocular Delivery

Development and Characterization of Indomethacin-Loaded Mucoadhesive Nanostructured Lipid Carriers for Topical Ocular Delivery

Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation

Nanoparticles for drug delivery to the anterior segment of the eye

Contact Info

Product

Resources

About